UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 32

Sortiert nach

On the TRAIL to successful cancer therapy? Predicting and counteracting resistance against TRAIL-based therapeutics

Oncogene, 2013-03, Vol.32 (11), p.1341-1350

2013

Volltextzugriff (PDF)

Expression of Six1 in luminal breast cancers predicts poor prognosis and promotes increases in tumor initiating cells by activation of extracellular signal-regulated kinase and transforming growth factor-beta signaling pathways

Breast cancer research : BCR, 2012-07, Vol.14 (4), p.R100-R100, Article R100

2012

Volltextzugriff (PDF)

Single-Fraction Stereotactic Body Radiation Therapy and Sequential Gemcitabine for the Treatment of Locally Advanced Pancreatic Cancer

International journal of radiation oncology, biology, physics, 2011-09, Vol.81 (1), p.181-188

2011

Volltextzugriff (PDF)

A Polygenic Risk Score Predicts Incident Prostate Cancer Risk in Older Men but Does Not Select for Clinically Significant Disease

Cancers, 2021-11, Vol.13 (22), p.5815

2021

Volltextzugriff (PDF)

Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study

The lancet oncology, 2023-05, Vol.24 (5), p.496-508

2023

Volltextzugriff (PDF)

Management of Locally Recurrent Retroperitoneal Sarcoma in the Adult: An Updated Consensus Approach from the Transatlantic Australasian Retroperitoneal Sarcoma Working Group

Annals of surgical oncology, 2022-11, Vol.29 (12), p.7335-7348

2022

Volltextzugriff (PDF)

Multicenter Phase II and Translational Study of Cetuximab in Metastatic Colorectal Carcinoma Refractory to Irinotecan, Oxaliplatin, and Fluoropyrimidines

Journal of clinical oncology, 2006-10, Vol.24 (30), p.4914-4921

2006

Volltextzugriff (PDF)

Hereditary diffuse gastric cancer: updated clinical practice guidelines

The lancet oncology, 2020-08, Vol.21 (8), p.e386-e397

2020

Volltextzugriff (PDF)

Genomic Complexity Profiling Reveals That HORMAD1 Overexpression Contributes to Homologous Recombination Deficiency in Triple-Negative Breast Cancers

Cancer discovery, 2015-05, Vol.5 (5), p.488-505

2015

Volltextzugriff (PDF)

Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials

The lancet oncology, 2018-01, Vol.19 (1), p.27-39

2018

Volltextzugriff (PDF)

ROR1 and ROR2 expression in pancreatic cancer

BMC cancer, 2021-11, Vol.21 (1), p.1199-1199, Article 1199

2021

Volltextzugriff (PDF)

Identification of a Small-Molecule Inhibitor That Disrupts the SIX1/EYA2 Complex, EMT, and Metastasis

Cancer research (Chicago, Ill.), 2020-06, Vol.80 (12), p.2689-2702

2020

Volltextzugriff (PDF)

Association Between Ageing and Short-Term Survival Outcomes in Patients Undergoing Surgery for Primary Retroperitoneal Sarcoma

Annals of surgical oncology, 2022-11, Vol.29 (12), p.7320-7330

2022

Volltextzugriff (PDF)

Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial

The lancet oncology, 2019-03, Vol.20 (3), p.420-435

2019

Volltextzugriff (PDF)

Development and Pilot Implementation of a Remote Monitoring System for Acute Toxicity Using Electronic Patient-Reported Outcomes for Patients Undergoing Radiation Therapy for Breast Cancer

International journal of radiation oncology, biology, physics, 2021-11, Vol.111 (4), p.979-991

2021

Volltextzugriff (PDF)

Genomic Risk Prediction for Breast Cancer in Older Women

Cancers, 2021-07, Vol.13 (14), p.3533

2021

Volltextzugriff (PDF)

ASO Visual Abstract: Association Between Ageing and Short-Term Survival Outcomes in Patients Undergoing Surgery for Primary Retroperitoneal Sarcoma

Annals of surgical oncology, 2022-11, Vol.29 (12), p.7333-7334

2022

Volltextzugriff (PDF)

Functional Transcription Factor Target Networks Illuminate Control of Epithelial Remodelling

Cancers, 2020-09, Vol.12 (10), p.2823

2020

Volltextzugriff (PDF)

Six1 overexpression in ovarian carcinoma causes resistance to TRAIL-mediated apoptosis and is associated with poor survival

Cancer research (Chicago, Ill.), 2007-04, Vol.67 (7), p.3036-3042

2007

Volltextzugriff (PDF)

TRAIL receptor signaling regulation of chemosensitivity in vivo but not in vitro

PloS one, 2011-01, Vol.6 (1), p.e14527-e14527

2011

Volltextzugriff (PDF)

Intensity‐modulated radiation therapy versus conventional radiation therapy for squamous cell carcinoma of the anal canal

Cancer, 2011-08, Vol.117 (15), p.3342-3351

2011

Volltextzugriff (PDF)

Molecular Cytogenetic Identification of Subgroups of Grade III Invasive Ductal Breast Carcinomas with Different Clinical Outcomes

Clinical cancer research, 2004-09, Vol.10 (18), p.5988-5997

2004

Volltextzugriff (PDF)

Distinct TRAIL Resistance Mechanisms Can Be Overcome by Proteasome Inhibition but not Generally by Synergizing Agents

Cancer research (Chicago, Ill.), 2011-03, Vol.71 (5), p.1883-1892

2011

Volltextzugriff (PDF)

A Genome-Wide Loss-of-Function Screen Identifies SLC26A2 as a Novel Mediator of TRAIL Resistance

Molecular cancer research, 2017-04, Vol.15 (4), p.382-394

2017

Volltextzugriff (PDF)

1 – 25 von 32

Suche als RSS-Feed

Aktive Filter

ThemaOncology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(29)
Mit Volltextzugriff
(30)

Publikationsform

Artikel
(31)
Bücher
(1)

Sprache

Englisch
(32)
Japanisch
(7)

Erscheinungsjahr

n.n

Thema

14 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

On the TRAIL to successful cancer therapy? Predicting and counteracting resistance against TRAIL-based therapeutics

Management of Primary Retroperitoneal Sarcoma (RPS) in the Adult: An Updated Consensus Approach from the Transatlantic Australasian RPS Working Group

Expression of Six1 in luminal breast cancers predicts poor prognosis and promotes increases in tumor initiating cells by activation of extracellular signal-regulated kinase and transforming growth factor-beta signaling pathways

Single-Fraction Stereotactic Body Radiation Therapy and Sequential Gemcitabine for the Treatment of Locally Advanced Pancreatic Cancer

A Polygenic Risk Score Predicts Incident Prostate Cancer Risk in Older Men but Does Not Select for Clinically Significant Disease

Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study

Management of Locally Recurrent Retroperitoneal Sarcoma in the Adult: An Updated Consensus Approach from the Transatlantic Australasian Retroperitoneal Sarcoma Working Group

Multicenter Phase II and Translational Study of Cetuximab in Metastatic Colorectal Carcinoma Refractory to Irinotecan, Oxaliplatin, and Fluoropyrimidines

Hereditary diffuse gastric cancer: updated clinical practice guidelines

Genomic Complexity Profiling Reveals That HORMAD1 Overexpression Contributes to Homologous Recombination Deficiency in Triple-Negative Breast Cancers

Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials

ROR1 and ROR2 expression in pancreatic cancer

Identification of a Small-Molecule Inhibitor That Disrupts the SIX1/EYA2 Complex, EMT, and Metastasis

Association Between Ageing and Short-Term Survival Outcomes in Patients Undergoing Surgery for Primary Retroperitoneal Sarcoma

Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial

Development and Pilot Implementation of a Remote Monitoring System for Acute Toxicity Using Electronic Patient-Reported Outcomes for Patients Undergoing Radiation Therapy for Breast Cancer

Genomic Risk Prediction for Breast Cancer in Older Women

ASO Visual Abstract: Association Between Ageing and Short-Term Survival Outcomes in Patients Undergoing Surgery for Primary Retroperitoneal Sarcoma

Functional Transcription Factor Target Networks Illuminate Control of Epithelial Remodelling

Six1 overexpression in ovarian carcinoma causes resistance to TRAIL-mediated apoptosis and is associated with poor survival

TRAIL receptor signaling regulation of chemosensitivity in vivo but not in vitro

Intensity‐modulated radiation therapy versus conventional radiation therapy for squamous cell carcinoma of the anal canal

Molecular Cytogenetic Identification of Subgroups of Grade III Invasive Ductal Breast Carcinomas with Different Clinical Outcomes

Distinct TRAIL Resistance Mechanisms Can Be Overcome by Proteasome Inhibition but not Generally by Synergizing Agents

A Genome-Wide Loss-of-Function Screen Identifies SLC26A2 as a Novel Mediator of TRAIL Resistance

Aktive Filter

Suchergebnisse filtern